Retinoblastoma Patient Clinical Database and Tissue Repository

Condition(s) studied

Study summary

Retinoblastoma (RB) is a primary eye cancer that forms in the back of the eye of infants and toddlers. Traditionally, RB is diagnosed without a biopsy; tumor can only be studied once an eye has been surgically removed.

Given this limitation, we use aqueous humor (AH), the clear fluid in the front of the eye to detect specific markers, or information, that comes from the tumor itself.

Eligibility

Primary outcome measure(s)

• Correlation of Ocular Salvage (eye saved) with biomarkers — through study completion, a minimum of 12 months after diagnosis and average of 24 months
  We aim to evaluate whether any identifiable molecular biomarkers (e.g. chromosomal alterations or tumor fraction) in the aqueous or blood can predict ocular salvage, or the likelihood of saving the eye with therapy
• Identification of RB1 (RB Transcriptional Corepressor 1) gene mutations from the AH liquid biopsy — through study completion, a minimum of 12 months after diagnosis and average of 24 months
  We aim to identify both somatic and germline RB1 gene mutations in the AH

Trial sites (9)

More Children's Hospital Los Angeles trials in Canada

Other trials for the same condition